Neurocognition and functional outcome in patients with psychotic, non-psychotic bipolar I disorder, and schizophrenia. A five-year follow-up
- 28 November 2018
- journal article
- research article
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 56 (1), 60-68
- https://doi.org/10.1016/j.eurpsy.2018.11.008
Abstract
Background: Bipolar disorder (BD) and schizophrenia (SZ) are characterized by neurocognitive and functional deficits with marked heterogeneity. It has been suggested that BD with a history of psychotic symptoms (BD-P) could constitute a phenotypically homogeneous subtype characterized by greater neurocognitive and functional impairments, or by a distinct trajectory of such deficits. The aim of this study was to compare the neurocognitive and functional course of euthymic BD-P, euthymic BD patients without a history of psychosis (BD-NP), stabilized patients with schizophrenia and healthy subjects, during a five-year follow-up. Methods: Neurocognitive and psychosocial function was examined in 100 euthymic patients with BD (50 BD-P, 50 BD-NP), 50 stabilized patients with schizophrenia (SZ), and 51 healthy controls (HC) at baseline (T1), and after a 5-year follow-up (T2). Results: The course of both neurocognitive performance and functional outcome of patients with SZ and BD (BD-P and BD-NP) is stable. The profile of neurocognitive impairment of patients with SZ or BD (BD-P and BD-NP), is similar, with only quantitative differences circumscribed to certain domains, such as working memory. The subgroup of patients with BD-NP does not show functional deterioration. Conclusions: We have not found evidence of progression in the neurocognitive or psychosocial impairment in any of the three groups of patients, although it cannot be dismissed the possibility of a subset of patients with a progressive course. Other longitudinal studies with larger samples and longer duration are necessary to confirm these findings. (c) 2018 Elsevier Masson SAS. All rights reserved.Keywords
Funding Information
- Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS)
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)
- Madrid Regional Government (S2010/BMD-2422 AGES, B2017/BMD-3740 AGES CM 2-CM)
- JanssenCilag
- Lundbeck
- Otsuka
- Pfizer
- Ferrer
- Juste
- Takeda
- AB-Biotics
- Allergan
- Angelini
- AstraZeneca
- Bristol-Myers Squibb
- Dainippon Sumitomo Pharma
- Farmindustria
- Ferrer
- Forest Research Institute
- Gedeon Richter
- Glaxo-Smith-Kline
- Janssen
- Lundbeck
- Otsuka
- Pfizer
- Roche
- Sanofi-Aventis
- Servier
- Shire
- Sunovion
- Takeda
- Brain and Behaviour Foundation
- Spanish Ministry of Science and Innovation (CIBERSAM)
- Seventh European Framework Programme (ENBREC)
- Stanley Medical Research Institute
This publication has 73 references indexed in Scilit:
- Antipsychotic-Associated Mental Side Effects and Their Relationship to Dopamine D2 Receptor Occupancy in Striatal SubdivisionsJournal of Clinical Psychopharmacology, 2011
- Neurocognitive Dysfunction in Bipolar and Schizophrenia Spectrum Disorders Depends on History of Psychosis Rather Than Diagnostic GroupSchizophrenia Bulletin, 2009
- Psychotic symptoms in patients with bipolar maniaJournal of Affective Disorders, 2008
- Short‐term course of neuropsychological abilities in middle‐aged and older adults with bipolar disorderBipolar Disorders, 2008
- The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and ValidityAmerican Journal of Psychiatry, 2008
- Psychotic features in bipolar and unipolar depressionBipolar Disorders, 2007
- Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorderClinical Practice and Epidemiology in Mental Health, 2007
- Mood disorder with psychotic features, schizoaffective disorder, and schizophrenia with mood features: Trouble at the bordersInternational Review of Psychiatry, 2005
- Association Between Cognitive Functioning and Employment Status of Persons With Bipolar DisorderPsychiatric Services, 2004
- Deficits in Sustained Attention in Schizophrenia and Affective Disorders: Stable Versus State-Dependent MarkersAmerican Journal of Psychiatry, 2002